Clinical Trials Logo

Clinical Trial Summary

Preventing carriage of potentially pathogenic micro-organisms from the aerodigestive tract is an infection control strategy used to reduce the occurrence of nosocomial infections - including ventilator-assisted pneumonia - in intensive care units. The use of antibiotics is controversial and can lead to adverse effect such as the selection of highly resistant pathogens. The purpose of this study was to investigate the effect of oral administration of a probiotic strain, Lactobacillus, on gastric and respiratory tract colonisation/infection by Pseudomonas aeruginosa strains, according to the concept that an indigenous flora has a protective effect against secondary colonisation.


Clinical Trial Description

In this prospective double-blind randomised study, ICU patients receive twice a day either an oral dose of Lactobacillus casei rhamnosus, the available pharmaceutical form, or a placebo. Digestive tract carriage of Pseudomonas aeruginosa is monitored by cultures of gastric aspirates. The occurrence of respiratory tract colonisations / infections is monitored throughout the study. Evaluation criteria are the delay and the rates of gastric P. aeruginosa colonisation and respiratory tract infection or colonisation. Chi-square or two tailed Fisher exact test are used for comparing qualitative variables and Student's t-test or mann-Whitney test for quantitatives variables. The mean of non-acquisition expectancy (NAE), length of stay without P. aeruginosa acquisition, was calculated and P. aeruginosa non-colonized patient rates were estimated and the two groups compared with regard to survival curves from grouped data using the Kaplan Meier method and the Logrank test. Variables with a P. value ≤0.15 in the univariate analysis were included in a logistic regression and a Cox regression model for multivariate analysis. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00621803
Study type Interventional
Source University Hospital, Clermont-Ferrand
Contact
Status Terminated
Phase N/A
Start date March 2003
Completion date October 2005

See also
  Status Clinical Trial Phase
Recruiting NCT03715322 - Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa Phase 3
Recruiting NCT03638830 - Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Phase 2
Completed NCT00235690 - Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036) N/A
Completed NCT00634192 - Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin Phase 3
Active, not recruiting NCT03510351 - Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
Recruiting NCT03044223 - Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
Terminated NCT00610623 - Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia Phase 2
Completed NCT00014950 - Benefits and Risks of Newborn Screening for Cystic Fibrosis N/A